Related Experiment Video
Updated: Feb 7, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational,
Mohamad Mohty1, Evangelos Terpos2, Maria-Victoria Mateos3
1Hematology and Cellular Therapy Department, Saint-Antoine Hospital, Pierre & Marie Curie University, Paris, France.
Background:
The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients.
Patients And Methods:
Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months.
Results:
A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide.
Conclusion:
The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.
Insights
Real-world data reveal diverse multiple myeloma (MM) treatment regimens and disease progression patterns. Novel agent accessibility and evolving guidelines influence treatment choices and clinical outcomes in MM patients.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Prospective, multinational, noninterventional study documenting real-world treatment and disease progression in multiple myeloma (MM).
- Focus on adult patients initiating new MM therapy between October 2010 and October 2012.
Purpose of the Study:
- To describe real-world treatment regimens and disease progression in multiple myeloma (MM).
- To investigate factors influencing treatment diversity and associated clinical benefits.
Main Methods:
- Multistage patient/site recruitment model to minimize selection bias, stratified by country, region, and practice type.
- Collected baseline data on patient features, disease, and treatment history.
- Prospective electronic data collection every 3 months on treatment, efficacy, and safety.
Main Results:
- 2358 patients enrolled; 775 underwent stem cell transplantation (SCT), 1583 did not.
- Significant diversity in treatment lines and use of bortezomib and/or thalidomide/lenalidomide, varying by SCT status.
- Overall response rates ranged from 86%-97% (SCT) and 64%-85% (non-SCT) in line 1, decreasing with subsequent lines.
Conclusions:
- Real-world practice shows significant diversity in MM treatment regimens.
- Treatment diversity is linked to novel agent accessibility and evolving treatment recommendations.
- Study provides insights into clinical benefits associated with diverse treatment approaches in MM.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:49Multiple Allele Traits
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies